Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma
AUTHORS: ASSUNTA DE RIENZO, MICHAEL A. ARCHER, BEOW Y. YEAP, ET. AL
A recent study by researchers at Brigham and Women’s Hospital and published in the Journal of Cancer Research explores gender differences in Mesothelioma. Different genetic mutations based upon mesothelioma subtypes may help explain the survival advantage to women who have this malignancy.
Lead author, Dr. De Rienzo discussed gender differences in genetic mutations:
- Female patients had twice as many mutations of the TP53 gene
- Women had much higher levels of the BAP 1 gene expression
- The CDKN2A protein coding gene mutated more frequently in men
She commented: “This will help apply personalized medicine for mesothelioma patients.”
Other researchers at Mount Sinai Health System and Hofstra School of Medicine, who analyzed SEER data in over 14,000 patients and found that the 5 year survival in women with mesothelioma was 13.4%, compared with a 4.5% survival rate in men.